These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 20170553

  • 1. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.
    BMC Cardiovasc Disord; 2010 Feb 22; 10():9. PubMed ID: 20170553
    [Abstract] [Full Text] [Related]

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct 22; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 3. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G, Mehta S.
    Appl Health Econ Health Policy; 2009 Oct 22; 7(1):43-59. PubMed ID: 19558194
    [Abstract] [Full Text] [Related]

  • 4. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M, Galiè N.
    J Am Coll Cardiol; 2009 Mar 03; 53(9):733-40. PubMed ID: 19245962
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar 03; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 6. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB, PACES Study Group.
    J Heart Lung Transplant; 2014 Jul 03; 33(7):689-97. PubMed ID: 24815795
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr 03; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov 03; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 9. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA.
    Pulm Pharmacol Ther; 2008 Oct 03; 21(5):824-32. PubMed ID: 18657627
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
    Valerio CJ, Handler CE, Kabunga P, Smith CJ, Denton CP, Coghlan JG.
    Rheumatology (Oxford); 2010 Nov 03; 49(11):2147-53. PubMed ID: 20675359
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.
    J Heart Lung Transplant; 2011 Dec 03; 30(12):1327-33. PubMed ID: 22055098
    [Abstract] [Full Text] [Related]

  • 12. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV.
    Eur J Clin Invest; 2006 Sep 03; 36 Suppl 3():10-5. PubMed ID: 16919005
    [Abstract] [Full Text] [Related]

  • 13. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.
    Chest; 2012 Dec 03; 142(6):1383-1390. PubMed ID: 22628490
    [Abstract] [Full Text] [Related]

  • 14. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Dec 03; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 15. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D, Humbert M, Hachulla E.
    Presse Med; 2006 Dec 03; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [Abstract] [Full Text] [Related]

  • 16. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC.
    Chest; 2008 Jul 03; 134(1):139-45. PubMed ID: 18403673
    [Abstract] [Full Text] [Related]

  • 17. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group.
    Ann Intern Med; 2008 Oct 21; 149(8):521-30. PubMed ID: 18936500
    [Abstract] [Full Text] [Related]

  • 18. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.
    Eur Respir J; 2007 Mar 21; 29(3):469-75. PubMed ID: 17079256
    [Abstract] [Full Text] [Related]

  • 19. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C, Chen J.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD004434. PubMed ID: 16856046
    [Abstract] [Full Text] [Related]

  • 20. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL, Michelakis ED.
    Curr Opin Cardiol; 2006 Jul 19; 21(4):385-92. PubMed ID: 16755209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.